Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Human Subject Research to Explore the HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan

NCT06665776 is registered in ClinicalTrials.gov with PharmaEssentia as lead sponsor.

NCT NCT06665776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06665776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Human Subject Research to Explore the HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan
Lead sponsor
PharmaEssentia
Phase
Observational
Overall status
Terminated
Start date
March 14, 2023
Completion date
May 27, 2026
Enrollment
485 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor malignancy